Home
DrugRxiv Drug Repurposing Network Medicine
REPO4EU Meet the team Drug Repurposing Research Collection Conference
Blog
Register Dashboard
Search
Home
DrugRxiv Drug Repurposing Network Medicine
REPO4EU Meet the team Drug Repurposing Research Collection Conference
My ScienceOpen

Register Dashboard
Search
Inviting an author to review:
Sodium butyrate ameliorates diabetic retinopathy in mice via the regulation of gut microbiota and related short-chain fatty acids
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
382
views
Article has an altmetric score of 8
2
references
 Top references
cited by
0
    
1 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    1
    shares
      250
      similar
       All similar
      scite_
      0
      0
      0
      0
      Smart Citations
      0
      0
      0
      0
      Citing PublicationsSupportingMentioningContrasting
      View Citations

      See how this article has been cited at scite.ai

      scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

      Version and Review History
      1
      Preprint Version
      Reviewed by Donald Lo
       
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      International Drug Repurposing Patent Landscaping, Part 1: Rare Diseases

      Preprint
      In review
      research-article
      Author(s):   1 ,
      Publication date (Electronic preprint):
      Journal: DrugRxiv
      Publisher: REPO4EU
      Keywords: drug repurposing, patenting, rare diseases
      Bookmark

            Revision notes

            -

            Abstract

            Content

            Author and article information

            Journal
            Title: DrugRxiv
            Publisher: REPO4EU
            Publication date (Electronic preprint): 2 April 2024
            Affiliations
            [1 ] H.M. Pharma Consultancy;
            Author notes
            Author information
            https://orcid.org/0000-0002-1491-6250
            Article
            DOI: 10.58647/DRUGARXIV.PR000009.v1
            SO-VID: 78ea5fc0-1d4e-4765-bde1-830c2aee768c
            License:

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            History
            Date received : 2 April 2024
            Funding
            Funded by: funder-id http://dx.doi.org/10.13039/100018696, HORIZON EUROPE Health;
            Award ID: 101057619
            Categories

            Data availability: The data that support the findings of this study are available from Dr. Hermann Mucke but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Dr. Hermann Mucke.
            ScienceOpen disciplines: Medicine,Life sciences
            Keywords: drug repurposing,patenting,rare diseases

            References

            1. Aartsma-Rus Annemieke, Dooms Marc, Le Cam Yann. Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group). Frontiers in Pharmacology. Vol. 12:2021. Frontiers Media SA. [Cross Ref]

            2. Mucke Hermann A.M., Mucke Eva. Sources and Targets for Drug Repurposing: Landscaping Transitions in Therapeutic Space. ASSAY and Drug Development Technologies. Vol. 13(6):319–324. 2015. Mary Ann Liebert Inc. [Cross Ref]

            Comments

            Comment on this article